Blog Viewer

NCRC Directors and INTREPID Grant Announcement

By Currents Editor posted 03-29-2018 23:00


Sara_Hocker__MD.bmpAndrew_Naidech__MD.bmpShraddha_Mainali__MD.bmpBy Sara Hocker, MD, Andrew Naidech, MD and Shraddha Mainali MD

The newly organized Neurocritical Care Research Central (NCRC) is pleased to announce that Drs. Javier Provencio and Paul Vespa have been appointed as its co-directors.

The selection process, previously outlined in the December 2017 issue of Currents, began with the convening of a five-member task force supervised by the Research Operations Subcommittee (ROS) tasked with selecting nominees. Fifteen nominees were selected based upon pre-specified criteria. Criteria included a track record of funded research and publication, collaboration, mentorship record, commitment to NCS, representation and ambassadorship of NCS to other professional societies, diversity of their background, training and practice,. Equal consideration was given to non-MD, non-neurology and international NCS members. The nominee list was further narrowed to nine candidates through review by the ROS and then to two candidates through review by the executive committee. They were confirmed via a vote by the NCS Board of Directors.

Dr. Javier Provencio is an associate professor of neurology and director of the University of Virginia Health System’s Nerancy Neuroscience ICU.

  • He is board-certified in internal medicine, neurology, critical care and neurocritical care, and is a fellow of the AAN, NCS and FCCM.
  • He trained as a post-doctoral fellowship in biology.
  • His research interests include innate inflammatory pathways associated with acute aneurysmal subarachnoid hemorrhage and cognitive outcomes associated with these inflammatory changes, as well as systemic normothermia in ICH.
  • He is a highly published investigator with funding from the National Institutes of Health and industry.
  • He is a frequent invited speaker at national and international conferences.
  • He has an excellent track record of good mentorship.
  • He is committed to NCS, having served as member of the Board of Directors for eight years, spoken frequently at the annual meeting and helped create a research career development course.
  • He has a presence in the SCCM and ESICM.

Dr. Paul Vespa is a professor of neurology and neurosurgery at the David Geffen UCLA School of Medicine where he is also division chief and director of the neurocritical care division and assistant dean for research in critical care medicine.

  • He is board-certified in neurology and neurocritical care, and is a fellow of the AAN, ANA, NCS and SCCM.
  • His clinical and research interests include multi-modality monitoring in traumatic brain injury, intracerebral hemorrhage, status epilepticus, stroke, subarachnoid hemorrhage and coma.
  • He has an outstanding record of publication of funded research with the National Institutes of Health, Department of Defense and industry.
  • He is a frequent invited speaker at national and international conferences.
  • He has an excellent track record of mentorship.
  • He has demonstrated clear commitment to NCS having served as member of the Board of Directors since 2005, as well as chair of both the fundraising and publication committees.
  • He has a presence in the SCCM and AAN.

New INTREPID-Grant Announced

The NCS has announced a new grant, Investing in Clinical Neurocritical Care Research (NCS-INCLINE) grant, at the 15th Annual Meeting in Waikoloa, Hawaii. The NCRC will administer and monitor this grant. This new research grant opportunity was developed for members to foster promising, innovative and collaborative research aimed at improving clinical outcomes in neuroscience critical care through clinical or translational research strategies. The grant provides one year of funding for multi-center pilot studies in neurocritical care that will enable the awardees to develop preliminary data in preparation for submission of a formal proposal to national funding agencies such as the National Institutes of Health, Department of Defense, PCORI etc. Though there is a distinct clinical focus to the objectives of this grant, translational studies that have direct application to clinical care will broadly remain under its scope. Preference will be granted to proposals that may be conducted as multi-center studies within the Neurocritical Care Research Network, but participation in other national and/or international networks will be acceptable. Active NCS members in good standing at all career stages are eligible to apply as long as the study requirements described in the FOA are met.  

Please direct any questions about the NCS-INCLINE grant to:

This grant is the product of several years of work by the NCS and board of directors to foster clinical research in neurocritical care by providing actual funding. NCS is re-investing money into its membership and is committed to keep up the line of funding for such research. The clinical research fellowship grant was the end of a long drought of funding by NCS, but was limited to junior investigators only. The INTREPID-grant is a funding opportunity for any member at any training level. The NCRC directors will soon name the members and chair of the Grants-subcommittee who will be reviewing the applications. We will continue to report on the outcome of this RFA.

Richard Choi, DO Please note this opinion piece reflects the views of the author and does not necessarily reflect the position of ChristianaCare.   The recent wave of increased social and racial injustice awareness as well as the significant increase in anti-Asian hate crimes 1 have had me ...
Lindner A, Rass V, Ianosi BA, et al. The Importance of PbtO2 Probe Location for Data Interpretation in Patients with Intracerebral Hemorrhage. Neurocritical Care . 2020 Sep 11:1-0.  Reviewed by Wazim Mohamed, MD Read the Article Background : Secondary brain injury after spontaneous intracerebral ...
By Wade Smith, MD, PhD, FNCS COVID-19 Vaccinations: Hope Is on the Horizon Dear NCS Members, As hopeful news about COVID-19 vaccines spreads nationwide, we can start looking forward to a safe return to our regular lives. Rates of hospitalizations have fallen across the United States. All ...